Company Profile

Inhibitor Therapeutics is a publicly traded, clinical stage pharmaceutical development company. We have a focus on developing and commercializing innovative therapies, using repurposed, already approved API’s (active pharmaceutical ingredients) that have clinical value and are patent protected. We have a significant amount of owned intellectual property around the use of itraconazole in oncology indications, especially in the treatment of Basal Cell Carcinoma Nevus Syndrome and both lung and prostate cancers.

Industry Classifications

Sector:

Healthcare

Industry:

Biotechnology

NAICS:

Pharmaceutical Preparation Manufacturing (325412)

SIC:

Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
Inhibitor Therapeutics, Inc.
Simon Bettink
VP of Operations
sbettink@inhibitortx.com

Company Contact
Inhibitor Therapeutics, Inc.
900 W Platt St
Suite 200
Tampa, FL 33606